Challenges and Future Directions of GLP-1 'Central Program' Intervention Current challenge: Individual differences and long-term safety Although GLP-1 injections have shown excellent efficacy in clinical trials, their "central plan" interventions still face challenges: Individual metabolic differences There are significant differences in the response of different patients to GLP-1RA, which are related to factors such as gene polymorphism, gut microbiota composition, and metabolic flexibility
Ability to Maintain Modified Training Complete rest deconditions cardiovascular fitness, weakens supporting muscles, and often leads to compensatory injuries upon return
Genetic Factors That Influence Your Sweet-Craving Response Individual differences in appetite regulation genes affect how strongly you respond to GLP-1 therapy and how dramatically your sugar cravings diminish
Scientific Basis and Practical Aspects of Creatine Supplementation for Athletes. Nutrition, vol
Why dosing should never be self-adjusted Adjusting your sermorelin dosing without direct medical advice is both unsafe and counterproductive
US approves first GLP-1 pill for weight loss: Novo Nordisk WASHINGTON - Danish pharmaceutical giant Novo Nordisk announced on Dec 22 the US Food and Drug Administration (FDA) had approved its popular GLP-1 anti-obesity drug Wegovy to be administered in pill form for weight loss
